Dynavax gets $50mm in special funding from Symphony
Executive Summary
Private equity firm Symphony Capital has formed financing and clinical development vehicle Symphony Dynamo and funded the new company with $50mm to continue development on Dynavax's cancer, hepatitis B and hepatitis C programs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Special-Purpose Financing Vehicle
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice